Content |
History
2022
Two sodas a day raise risk of obesity-related cancer death
On September 15, 2022, a study was published, according to which people who drink two or more servings of sugar-sweetened drinks (PSN) per day are more likely to die from cancer caused by obesity, including cancers of the gastrointestinal tract, kidneys, postmenopausal breast and endometrium.
The Specialist American oncological Led Society (ACS) study focused on PSNs and their relationship to the likelihood of death from various cancers. The study analyzed data the consumption habits of more than 900 thousand people who did not have cancer in 1982, and in 2016 a second analysis was carried out.
A 2016 analysis found that 135,093 participants died of cancer, and consideration of the relationship with drinking habits allowed for a number of conclusions. Men and women drinking two or more servings (one serving is 355 ml) of PSN per day were found to be 5% more likely to die from not all cancers, namely obesity-related cancer. After adjusting for body mass index (BMI), this increased probability was found to be zero.
{{quote 'Alas, Americans are increasingly exceeding the sugar intake rates set by US dietary guidelines, and sugar-sweetened beverages are well-known factors in weight gain, overweight and obesity, "notes Marjorie McCullough, senior scientific director of epidemiological research at ACS and the study's lead author. The results of our study support recommendations to limit the consumption of sugar-sweetened beverages included in the ACS Dietary and Physical Activity Guidelines for Cancer Prevention to reduce the risk of developing this disease. }} The scientists concluded that the increase in mortality from consumption of sugar-sweetened beverages is partly mediated by obesity, and that future studies should consider the role of body mass index in studying the risk of cancer from consumption of sweetened beverages.[1]
Artificial sweeteners increase cardiovascular risk by 9%
On September 11, 2022, a study was published, according to which there is a direct correlation between high consumption of artificial sweeteners and increased overall risk of developing cardiovascular disease (CVD), including cardiometabolic disorders. It turned out that caviar sweeteners increase the risk of cardiovascular disease by 9%.
The researchers examined artificial sweeteners from different food sources, such as sweetened beverages, tableted sweeteners and dairy products, and their molecular composition, specifically aspartame, acesulfame potassium and sucralose.
In the study, the scientists included 103,388 participants in a sample of NutriNet-Sante in France to assess their dietary intake and consumption of artificial sweeteners. The group further used multivariable-adjusted Cox risk models to assess the correlation between sweeteners and CVD risk. They calculated each type of cerebrovascular and coronary impairment separately, including myocardial infarction, angioplasty, angina, stroke, acute coronary syndrome, and transient ischemia. Both self-reported and medico-administrative data were used to determine CVD outcomes.
In the NutriNet-Sante sample, 37.1% of participants consumed artificial sweeteners. The contribution of aspartame, acesulfame potassium and sucralose to the total consumption of artificial sweeteners was 58%, 29% and 10%, respectively.
Eating artificial sweeteners increased the risk of cardiovascular disease by 9%. The closest correlation was found between the use of artificial sweeteners and cerebrovascular disorders (stroke and transient ischemic attack) - the risk increased by 18%.
Aspartame increased the risk of cerebrovascular disorders by 17%, and acesulfame potassium and sucralose increased the risk of coronary heart disease by 4% and 31%, respectively.
The authors noted 1,502 cases of cardiovascular disease over an average follow-up of nine years. Of these, 730 cases of coronary heart disease and 777 cases of cerebrovascular disease. Notably, replacement of artificial sweeteners with supplemental sugars did not result in reduced CVD risk or improved CVD outcomes.[2]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |